In the past, biopsy was reserved to unusual cases or to cases enrolled in a clinical trial [122] while nowadays tissue sampling is indicated for patients with non-NF-1 associated optic pathway gliomas and for those with NF-1 who demonstrate relevant mass effect or obvious progression of the disease or may have particularly atypical imaging features [123–126]. The gene discussed is NF1; the disease is optic pathway glioma.